Yahoo
OTC Markets OTCPK - Delayed Quote USD

Santen Pharmaceutical Co., Ltd. (SNPHY)

11.23 +0.45 (+4.17%)
At close: October 30 at 4:00:00 PM EDT
View in AlphaSpace Currency in JPY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
3/31/2026
3/31/2025
3/31/2024
3/31/2023
Total Revenue
291,844,000
291,624,000
300,004,000
301,965,000
279,037,000
Cost of Revenue
119,232,000
121,881,000
128,977,000
123,256,000
112,950,000
Gross Profit
172,612,000
169,743,000
171,027,000
178,709,000
166,087,000
Operating Expense
124,270,000
121,945,000
124,147,000
140,169,000
169,177,000
Operating Income
48,342,000
47,798,000
46,880,000
38,540,000
-3,090,000
Net Non Operating Interest Income Expense
-14,000
-355,000
1,286,000
-1,092,000
-346,000
Pretax Income
48,327,000
47,442,000
47,481,000
29,874,000
-5,799,000
Tax Provision
9,429,000
9,881,000
11,628,000
3,171,000
9,184,000
Net Income Common Stockholders
38,677,000
37,361,000
36,247,000
26,642,000
-14,948,000
Average Dilution Earnings
--
9,000
9,000
--
--
Diluted NI Available to Com Stockholders
38,685,000
37,369,000
36,256,000
26,642,000
-14,948,000
Basic EPS
119.10
114.04
103.98
72.59
-38.60
Diluted EPS
118.82
113.80
103.68
72.37
-38.60
Basic Average Shares
323,168.21
327,624
348,605
366,890
387,420.47
Diluted Average Shares
323,983.72
328,374
349,694
368,139
387,420.47
Total Operating Income as Reported
48,340,000
47,797,000
46,880,000
38,541,000
-3,090,000
Total Expenses
243,502,000
243,826,000
253,124,000
263,425,000
282,127,000
Net Income from Continuing & Discontinued Operation
38,685,000
37,369,000
36,256,000
26,642,000
-14,948,000
Normalized Income
38,685,000
37,369,000
36,256,000
26,642,000
-14,948,000
Interest Income
1,969,000
1,639,000
4,002,000
1,572,000
1,153,000
Interest Expense
1,983,000
1,994,000
2,716,000
2,664,000
1,499,000
Net Interest Income
-14,000
-355,000
1,286,000
-1,092,000
-346,000
EBIT
50,310,000
49,436,000
50,197,000
32,538,000
-4,300,000
EBITDA
59,204,000
58,209,000
59,009,000
50,716,000
12,949,000
Reconciled Cost of Revenue
119,232,000
121,881,000
128,977,000
123,256,000
112,950,000
Reconciled Depreciation
8,894,000
8,773,000
8,812,000
18,178,000
17,249,000
Net Income from Continuing Operation Net Minority Interest
38,685,000
37,369,000
36,256,000
26,642,000
-14,948,000
Normalized EBITDA
59,204,000
58,209,000
59,009,000
50,716,000
12,949,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
3/31/2023 - 8/31/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: